J&J pol­ish­es up its new list of late-stage block­buster can­di­dates — and can­cer re­mains big

J&J’s R&D group at Janssen has al­ways kept its eyes on the block­buster prize with a reg­u­lar look at its top prospects in the pipeline. Now — af­ter some fail­ures and ap­provals — it’s of­fered up its lat­est ros­ter of 10 top can­di­dates for $1 bil­lion-plus in rev­enue with po­ten­tial ap­provals through the next 4 years. And there are some new drugs mixed in with some old fa­vorites.

In a day-long busi­ness re­view on Wednes­day, R&D chief Math­ai Mam­men spot­light­ed these 10 drugs as their most promis­ing pro­grams

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER